Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Hemostasis Analyzers Market Driven by Increasing Awareness of Blood Disorder Conditions

By LabMedica International staff writers
Posted on 09 Feb 2023

Hemostasis analyzers are devices used for measuring clotting mechanisms of hemostasis in order to detect clotting deficiencies. The body’s natural ability to quickly stop bleeding in order to stop serious blood loss is known as hemostasis. Hemostasis analyzers are used to perform tests such as APTT tests, D dimer tests, platelet function tests, fibrinogen tests, prothrombin time tests, and other tests using optical technology, mechanical technology, electrochemical technology, and other technologies. Within hemostasis analyzers, the main products are clinical laboratory analyzers, point-of-care testing analyzers, and consumables. Clinical laboratory analyzers are used to calculate the concentration of certain substances in various samples. The various end users of hemostasis analyzers are hospitals and clinics, diagnostic centers, research and development organizations and ambulatory surgical centers, among others.

The global hemostasis analyzers market is expected to reach USD 5.97 billion in 2026, driven by the increasing awareness of blood disorder conditions such as Hemophilia and Von Willebrand disease (vWD) which are genetic disorders and not well known to people. This results in late diagnosis of blood disorders and affects patient outcomes. The increasing awareness is expected to improve the diagnosis rate of blood disorders, thereby driving the demand for hemostasis analyzers. However, recalls of defective devices could act as a restraint to the growth of the hemostasis analyzers market. These are the latest findings of ReportLinker (Lyon, France), a market research solution provider.

The hemostasis analyzers market consists of sales of complete blood count (CBC), factor v assay, fibrinogen level, prothrombin time (PT or PT-INR), platelet count, and thrombin time. Manufacturers of hemostasis analyzers are developing portable, handheld hemostasis analyzers which are convenient for carrying anywhere and are small enough to fit in a person's palm. These portable hemostasis analyzers offer a quicker and easier testing process, and facilitate independent analysis of results. Geographically, North America dominated the global hemostasis analyzers market in 2022 with the largest share, followed by Western Europe with the second-largest share.

Related Links:
ReportLinker 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Coagulation Analyzer
CS-2400
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.